Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex in high-risk ambulatory surgeries
NCT03944473Phase 4Withdrawn
- Sponsor
- Montefiore Medical Center
- Start
- Jun 2019
- Primary completion
- Jul 2020
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Montefiore Medical Center. Primary endpoints: Aldrete Score up to 5 hours, Post Anesthetic Discharge Scoring System up to 5 hours and 1 more. Planned start Jun 2019; status: withdrawn.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03944473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944473.